Helveteq, a Swiss issuer of ESG-transparent investment products, is launching a pioneering and unique solution for ecological and sustainable investments in gold. The company has issued and listed a new exchange traded product (ETP) on
Alessandro Celli, partner at Baker McKenzie Switzerland, speaks. “We have created a data-driven team.” by giuseppe salemme Alessandro Celli is a partner at Baker Mckenzie Switzerland and head of the Swiss Tmt practice group. He
NKF advised Ecorobotix as Swiss counsel on its CHF 46 million Series B Prime financing round led by AQTON Private Equity and Cibus Capital. Additional investments came from Swisscanto Invest/Swisscanto Growth Fund I, Yara Growth
With the legal representation by Lenz & Staehelin‘s Jürg Simon (pictured) and Milano based legal professional, Cesare Galli, Emmentaler Switzerland, the producer organization of Emmentaler AOP, has recently achieved a significant victory in
Walder Wyss team advised the funds managed by Pharmakon Advisors, LP, in connection with the closing of the term loan financing of Reata Pharmaceuticals for up to USD 275 million. Reata Pharmaceuticals, is a global biopharmaceutical
Siegfried and DiNAQOR entered into an agreement relating to the acquisition by Siegfried of a 95% stake in DiNAQOR DiNAMIQS, a Swiss-based biotechnology company focused on the development and manufacturing of viral vectors for cell and
Daniel Haymann joins MME from MLL and becomes Counsel. He specialises in corporate and commercial law. Based on his extensive business experience, he has a good feel for new markets and understands the requirements of
Emergent BioSolutions, the New York Stock Exchange listed developer and manufacturer of vaccines, completed the sale of its travel vaccine business to Bavarian Nordic for an upfront payment of USD 270 million. At closing Emergent received
NewBiologix, a technology company developing a proprietary platform focused on engineering cell lines used to manufacture gene and cell therapies, raised USD 50 million in series A financing. The round was led by Recipharm (an EQT
DSM and Firmenich have successfully concluded their merger announced on 31 May 2022, becoming a powerful creation and innovation partner in nutrition, beauty, and well-being. The EUR 35 billion business combination solidifies their position in the industry.
